Biogen Pharmachem Industries (531752) Q4 12/13 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 12/13 earnings summary
26 Oct, 2026Executive summary
FY2012-13 operations generated no revenue; net loss widened to ₹1,339,054 from ₹950,036 YoY amid sluggish markets and financial stress.
Management said it was taking steps to strengthen operations and viability, and expected turnover to improve despite possible industry recession.
Financial highlights
Total revenue was nil versus ₹441,181 in FY2011-12; total expenses fell to ₹1,339,054 from ₹1,391,217.
Net loss was ₹1,339,054, compared with ₹950,036 in FY2011-12; no tax expense or exceptional or extraordinary items were recorded.
Total assets and liabilities were ₹651.4m at 31 Mar 2013, down from ₹671.8m a year earlier.
Cash and cash equivalents closed at ₹926,939, versus ₹1,205,159 at 31 Mar 2012.
Outlook and guidance
Management expected turnover to improve, citing strong fundamentals of Indian businesses, while acknowledging possible recessionary industry conditions.
Latest events from Biogen Pharmachem Industries
- Q2 returned to profit, while H1 revenue and net profit declined YoY.531752
Q2 26/27 - Revenue contracted sharply as profits narrowed; outlook centered on commodity trading and wind power.531752Q4 06/07
- FY08 trading contracted sharply, with conflicting reported profit figures and planned wind-power expansion.531752Q4 07/08
- Trading expanded, but a ₹43.33m loss and accumulated-loss risks overshadowed growth plans.531752Q4 08/09
- Net loss narrowed sharply, while preference warrants and corporate advances expanded the balance sheet.531752Q4 09/10
- FY12 loss narrowed, but weak markets constrained revenue and management looked to rebuild turnover.531752Q4 11/12
- Nil operating revenue, a ₹1.30 million loss and sharply higher short-term borrowings marked FY14.531752Q4 13/14
- No operations, nil operating revenue, and a ₹1.33m FY15 net loss amid working-capital constraints.531752Q4 14/15
- Nil revenue and working-capital constraints kept operations inactive; FY15/16 net loss was ₹281,764.531752Q4 15/16